Atlas Venture Life Science Advisors, LLC Q1 2022 Filing

Filed May 16, 2022

Portfolio Value

$791.0M

Holdings

17

Report Date

Q1 2022

Filing Type

13F-HR

All Holdings (17 positions)

#StockSharesValue% PortfolioType
1
KYMRKymera Therapeutics, Inc.
6,875,698$291.0M36.79%
2
DYNDyne Therapeutics, Inc.
8,934,902$86.1M10.89%
3
DAWNDay One Biopharmaceuticals, Inc.
8,201,638$81.4M10.29%
4
GBIOGBXGeneration Bio, Co.
8,278,876$60.8M7.68%
5
AVTEAerovate Therapeutics, Inc.
3,103,879$56.9M7.19%
6
REPLReplimune Group, Inc.
3,209,627$54.5M6.89%
7
VIGLVigil Neuroscience, Inc.
5,836,874$41.0M5.19%
8
AKROAkero Therapeutics, Inc.
2,232,251$31.7M4.00%
9
Ikena Oncology, Inc.
5,018,178$30.6M3.87%
10
XLOXilio Therapeutics, Inc.
2,759,344$19.5M2.47%
11
Magenta Therapeutics, Inc.
3,476,536$10.1M1.27%
12
SPROSpero Therapeutics, Inc.
1,031,160$9.0M1.13%
13
Gemini Therapeutics, Inc.
5,254,365$7.3M0.92%
14
AvroBio, Inc.
4,520,863$6.0M0.75%
15
F-star Therapeutics, Inc.
599,524$2.1M0.27%
16
VRDNViridian Therapeutics, Inc.
90,072$1.7M0.21%
17
COGTCogent Biosciences, Inc.
186,487$1.4M0.18%